Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-STNV in Advanced Solid Tumors
NCT04665921Phase 1Terminated
- Sponsor
- Seagen Inc.
- Start
- Jan 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of sgn-stnv in non-small cell lung cancer (NSCLC), breast cancer, ovarian cancer and 8 more, sponsored by Seagen Inc. Primary endpoints: Incidence of adverse events (AEs) up to 3 years, Incidence of laboratory abnormalities up to 3 years and 1 more. Started Jan 2021; status: terminated.
02
Drugs
sgn-stnv
03
Conditions
non-small cell lung cancer (NSCLC)breast cancerovarian cancerCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04665921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665921.